MAIN OUTCOMES AND MEASURES
Serologic noninferiority of neutralizing antibody responses compared with those in young adults (aged 18–25 years) in PREVENT-19, protective efficacy against laboratory-confirmed COVID-19, and assessment of reactogenicity and safety.